TEIJIN PHARMA LIMITED | News Release

Latest News Release

Nov. 27, 2025	Teijin Pharma to Receive $5 Million Milestone Payment from Bioprojet for Initiating Phase 1 Clinical Trial of Narcolepsy Drug Candidate
Nov. 06, 2025	Teijin Pharma Launches YORVIPATH®, a First of its Kind Treatment in Japan for the Rare Disease Hypoparathyroidism
Oct. 23, 2025	Teijin Pharma Signs Licensing Agreement Giving UK Biotech Firm Exclusive Global Development and Commercialization Rights to Rheumatoid Arthritis Drug Candidate
Aug. 25, 2025	Teijin Pharma Receives Manufacturing and Marketing Approval in Japan for YORVIPATH® as the Treatment for Hypoparathyroidism
Jun. 24, 2025	Teijin Pharma Receives Approval for Additional Indication for XEOMIN® in Japan
Jun. 03, 2025	Navepegritide Designated as an Orphan Drug by Japan’s Ministry of Health, Labor and Welfare
Dec. 13, 2024	Teijin Pharma Limited Applies for Manufacturing and Marketing Approval in Japan for New Hypoparathyroidism Treatment
Apr. 10, 2024	Teijin Pharma Grants Global Exclusive License to Bioprojet to Develop a New Orexin Receptor 2 Agonist Investigational Candidate for Narcolepsy
Feb. 13, 2024	Teijin and Axcelead to Determine the Name of Drug Discovery Research JV
Nov. 29, 2023	Notice Concerning a Decision on the Licensing Agreement related to the Three Hormone Therapy Drugs for Rare Endocrine Diseases